Haoxi Health Technology Ltd
corporate_fare Company Profile
Haoxi Health Technology Ltd (NASDAQ:HAO) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 18 items for HAO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for HAO spans F-3, 20-F, 6-K, 424B5.
Recent high-impact activity:
- Haoxi Files $180M Shelf, But Float Is Only $1.85M — I.B.5 Caps Real Sales
- Haoxi Health FY2026: Revenue Up 67% But $9.5M Loss, Material Weaknesses, and Massive Authorized Share Increase
- Haoxi Health Closes $4M Registered Direct Offering at $0.40/Share, Initially Issuing 5.1M Shares
- Haoxi Health locks in $4M registered direct offering at $0.40/share, layering on pre-funded warrants
- $4M Direct Offering at 38% Discount Deepens Dilution for Cash-Strapped Haoxi
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 49,251 shares in HAO as of the October 30, 2026 settlement, a 54.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 2.4% of HAO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for HAO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-13.
$4M Registered Direct Offering Priced at $0.40/Share · Extreme Dilution from Pre-Funded Warrants
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
HAO files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.